Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea · Delayed Price · Currency is KRW 16,330
-570 (-3.37%)
At close: Jun 5, 2026
Cell Biotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 13,407 | 10,125 | 15,127 | 6,304 | 8,281 | 10,383 |
Depreciation & Amortization | 3,597 | 3,614 | 3,872 | 3,904 | 3,638 | 3,789 |
Loss (Gain) From Sale of Assets | 138.43 | 108.08 | -10.14 | 82.45 | 0.91 | -29.05 |
Loss (Gain) From Sale of Investments | -584 | -868.86 | -575.56 | 211.19 | - | -111.68 |
Provision & Write-off of Bad Debts | 1.52 | 8.95 | 1.44 | -0.1 | -0.39 | -0.44 |
Other Operating Activities | -2,643 | -1,336 | 167.48 | -215.9 | 154.35 | 441.37 |
Change in Accounts Receivable | -745.1 | -140.62 | 817.31 | 51.01 | 39.38 | 144.48 |
Change in Inventory | -474.47 | -412.51 | -81.6 | -19.33 | -506.84 | -79.79 |
Change in Accounts Payable | 187.24 | -504.21 | 38.76 | -875.33 | 96.3 | 271.08 |
Change in Unearned Revenue | 3.12 | 5.7 | 0.54 | -3.86 | -19.54 | 8.92 |
Change in Income Taxes | - | - | - | -643.39 | - | - |
Change in Other Net Operating Assets | 337.01 | 509.17 | -90.03 | -979.12 | 1,131 | 74.98 |
Operating Cash Flow | 13,225 | 11,109 | 19,267 | 7,815 | 12,814 | 14,892 |
Operating Cash Flow Growth | -24.75% | -42.34% | 146.53% | -39.01% | -13.96% | 55.71% |
Capital Expenditures | -7,249 | -3,105 | -1,129 | -1,552 | -2,368 | -848.59 |
Sale of Property, Plant & Equipment | 32.57 | 63.48 | 79.5 | 0 | 1.7 | 16.77 |
Sale (Purchase) of Intangibles | -14.12 | 2.14 | -113.83 | -123.92 | -304.2 | 25.86 |
Sale (Purchase) of Real Estate | - | - | - | - | - | 14.92 |
Investment in Securities | 5,510 | 7,562 | -17,685 | -3,062 | -4,138 | -10,499 |
Other Investing Activities | 44.79 | 32.73 | 213.05 | 12.17 | 38.62 | 2.6 |
Investing Cash Flow | -1,641 | 4,590 | -18,737 | -4,745 | -6,669 | -11,132 |
Long-Term Debt Repaid | - | -612.73 | -661.5 | -641.07 | -636.49 | -676.15 |
Net Debt Issued (Repaid) | -613.89 | -612.73 | -661.5 | -641.07 | -636.49 | -676.15 |
Repurchase of Common Stock | - | - | - | - | -3,719 | - |
Dividends Paid | -3,080 | -3,080 | -3,080 | -3,080 | -3,182 | -3,182 |
Financing Cash Flow | -3,694 | -3,692 | -3,741 | -3,721 | -7,538 | -3,858 |
Foreign Exchange Rate Adjustments | 647.06 | 375.56 | 83.65 | 76.91 | -9.33 | 357.88 |
Miscellaneous Cash Flow Adjustments | - | 0 | - | 0 | -0 | - |
Net Cash Flow | 8,537 | 12,382 | -3,128 | -573.48 | -1,402 | 260.35 |
Free Cash Flow | 5,975 | 8,004 | 18,138 | 6,264 | 10,445 | 14,044 |
Free Cash Flow Growth | -63.83% | -55.87% | 189.57% | -40.03% | -25.62% | 116.55% |
Free Cash Flow Margin | 10.58% | 15.07% | 36.34% | 11.65% | 20.67% | 29.96% |
Free Cash Flow Per Share | 873.42 | 1169.58 | 2649.95 | 915.24 | 1515.03 | 1985.94 |
Cash Interest Paid | 26.18 | 32.59 | 60.88 | 61.95 | 37.49 | 42.48 |
Cash Income Tax Paid | 2,391 | 2,423 | -1,539 | 1,355 | 1,371 | -136.75 |
Levered Free Cash Flow | 2,327 | 3,780 | 9,753 | -335.57 | 5,547 | 9,207 |
Unlevered Free Cash Flow | 2,343 | 3,800 | 9,791 | -296.85 | 5,571 | 9,233 |
Change in Working Capital | -692.2 | -542.47 | 684.99 | -2,470 | 740.73 | 419.67 |